Clot-Busting Drugs for Ischemic Stroke

How does intravenous thrombolysis treat ischemic stroke?

Most strokes are ischemic, caused by a clot that blocks an artery supplying the brain. Thrombolytic drugs work by activating plasminogen to form plasmin, an enzyme that breaks down fibrin, the protein mesh that holds a clot together. Alteplase was approved by the U.S. FDA for acute ischemic stroke in 1996 and has long been the standard agent given by vein within a defined time window after symptoms begin.

Because brain tissue is lost rapidly during a stroke, with one widely cited estimate suggesting roughly 1.9 million neurons are lost each minute in a large-vessel stroke, the benefit of treatment is strongly time-dependent. The main risk is bleeding, including symptomatic intracranial hemorrhage, so careful patient selection and a rapid brain scan to exclude hemorrhagic stroke are essential before treatment.

What are the new directions in stroke thrombolysis?

Tenecteplase, a genetically modified clot-busting drug that can be given as a single bolus rather than an infusion, has been studied against alteplase in several clinical trials, and the FDA approved it for acute ischemic stroke in 2025. Its simpler administration may help hospitals treat patients faster, particularly in settings where transfer to another facility is needed. Guidelines and national practices continue to evolve as more data emerge.

Advanced imaging such as perfusion CT or MRI can identify patients whose brain tissue may still be salvageable beyond standard time limits, or whose stroke onset time is unknown, such as those who wake up with symptoms. Trials including EXTEND and WAKE-UP, published in the New England Journal of Medicine, supported imaging-based selection in some of these patients. For people with a large-vessel occlusion, thrombolysis is often combined with mechanical thrombectomy, a procedure that physically removes the clot. Researchers continue to study which patients benefit most from each approach.

Why does getting to hospital fast still matter most?

Even the most advanced thrombolytic drug cannot help if a patient arrives too late or is not recognized as having a stroke. Public health campaigns teach warning signs such as sudden facial drooping, arm weakness, speech difficulty, loss of vision or balance, and severe sudden headache. The World Stroke Organization estimates that over 12 million people experience a first stroke each year worldwide, underscoring the scale of the problem.

Systems of care, including ambulance pre-notification, rapid brain imaging and streamlined in-hospital pathways, can shorten the time from arrival to treatment. Stroke is a medical emergency, and people should not wait to see whether symptoms resolve, drive themselves, or seek care from a non-emergency source. Eligibility for thrombolysis is determined by clinicians based on timing, scan results and medical history.